Primary endpoints and components in the ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), and REWIND (dulaglutide) trials (22–26,28). ns, not significant.
Sign In or Create an Account